Monday, June 4, 2018

Marriott Marquis Washington, DC
Independence E-G, Level 4
Washington, DC

6:00 pm - 6:30 pm Registration and Dinner
6:30 pm - 8:00 pm CME-certified Symposium

Slide to view more

Program Overview

Biosimilars are very much alike but not identical to an FDA-approved reference biologic compound, with no meaningful differences in quality, safety, or efficacy. Used widely in Europe since 2006, the first biosimilar agent for use in the United States was approved in March 2015, and now several biosimilars are FDA-approved. As more biosimilars become available for use in the United States, all members of the multidisciplinary care team will require education on the appropriate incorporation of these agents into existing treatment paradigms. The faculty of this CME activity will provide an overview of biosimilars as well as a review of the latest safety and efficacy data regarding the use of biosimilars relevant to gastroenterology.


6:30 pm – 6:40 pm Introduction and Pretest
David T. Rubin, MD, AGAF
6:40 pm – 7:05 pm Update on Biologics in IBD
Bruce E. Sands, MD, MS, AGAF
7:05 pm – 7:30 pm Clinical Review and Application of Biosimilars in Gastroenterology
Iris Dotan, MD
7:30 pm – 7:45 pm Panel Discussion – Optimal Use of Biologics in IBD
David T. Rubin, MD
7:45 pm – 7:50 pm Postest
7:50 pm – 8:00 pm Question and Answer

Slide to view agenda

CME Information

Target Audience

The intended audience for the activities is gastroenterologists and other health care professionals involved in the treatment of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon successful completion of this activity, participants will be able to:

  • Incorporate the latest information about biologics for IBD patients.
  • Compare biosimilars to both small molecule generic therapies and their reference biologic based on structure, manufacturing, regulation, and/or clinical properties.
  • Review the latest safety and efficacy data regarding the use of biologics relevant to IBD.
  • Describe strategies to educate patients regarding biologics and the importance of open communication regarding their concerns.